Micronomicin, also known as Sagamicin, is a broad-spectrum aminoglycoside antibiotic. It is structurally characterized as a 6'-N-methyl derivative of gentamicin C1a, belonging to the gentamicin complex family. This modification contributes to its antibacterial profile and pharmacokinetic properties. Its primary and definitive application is as an active pharmaceutical ingredient (API) for the treatment of serious bacterial infections. Micronomicin exhibits potent activity against a wide range of Gram-negative bacteria, including Pseudomonas aeruginosa, and some Gram-positive bacteria. It functions by binding to the bacterial 30S ribosomal subunit, thereby inhibiting protein synthesis and leading to bacterial cell death. It is used clinically, particularly in regions like Japan, for infections where other aminoglycosides may be less effective or for patients with specific resistance patterns. As an aminoglycoside, it is a complex molecule containing amino sugars (aminocyclitols) linked by glycosidic bonds, placing it within the category of bioactive carbohydrate derivatives. Its use requires careful therapeutic drug monitoring due to potential dose-related nephrotoxicity and ototoxicity, common to the aminoglycoside class.